Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules

Giovanna Lollo, Kevin Matha, Martina Bocchiardo, Jérôme Bejaud, Ilaria Marigo, Angelique Virgone-Carlotta, Thomas Dehoux, Charlotte Rivière, Jean Paul Rieu, Stephanie Briançon, Thomas Perrier, Olivier Meyer, Jean Pierre Benoit

Research output: Contribution to journalArticle

Abstract

In this work, a novel lipophilic 5-fluorouracil (5-FU) derivative was synthesised and encapsulated into lipid nanocapsules (LNC). 5-FU was modified with lauric acid to give a lipophilic mono-lauroyl-derivative (5-FU-C12, MW of about 342 g/mol, yield of reaction 70%). 5-FU-C12 obtained was efficiently encapsulated into LNC (encapsulation efficiency above 90%) without altering the physico-chemical characteristics of LNC. The encapsulation of 5-FU-C12 led to an increased stability of the drug when in contact with plasma being the drug detectable until 3 h following incubation. Cytotoxicity assay carried out using MTS on 2D cell culture showed that 5-FU-C12-loaded LNC had an enhanced cytotoxic effect on glioma (9L) and human colorectal (HTC-116) cancer cell line in comparison with 5-FU or 5-FU-C12. Then, HCT-116 tumour spheroids were cultivated and the reduction of spheroid volume was measured following treatment with drug-loaded LNC and drugs alone. Similar reduction on spheroids volume was observed following the treatment with drug-loaded LNC, 5-FU-C12 and 5-FU alone, while blank LNC displayed a reduction in cell viability only at high concentration. Globally, our data suggest that the encapsulation increased the activity of the 5-FU-C12. However, in-depth evaluations of LNC permeability into spheroids are needed to disclose the potential of these nanosystems for cancer treatment.

Original languageEnglish
Pages (from-to)1-12
Number of pages13
JournalJournal of Drug Targeting
DOIs
Publication statusAccepted/In press - Nov 21 2018

Fingerprint

Nanocapsules
Fluorouracil
Lipids
Pharmaceutical Preparations
Neoplasms
lauric acid
Drug Stability
Glioma
Permeability
Cell Survival

Keywords

  • 5-Fluorouracil
  • cancer treatment
  • lipid nanoparticles
  • nanomedicine

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Lollo, G., Matha, K., Bocchiardo, M., Bejaud, J., Marigo, I., Virgone-Carlotta, A., ... Benoit, J. P. (Accepted/In press). Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules. Journal of Drug Targeting, 1-12. https://doi.org/10.1080/1061186X.2018.1547733

Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules. / Lollo, Giovanna; Matha, Kevin; Bocchiardo, Martina; Bejaud, Jérôme; Marigo, Ilaria; Virgone-Carlotta, Angelique; Dehoux, Thomas; Rivière, Charlotte; Rieu, Jean Paul; Briançon, Stephanie; Perrier, Thomas; Meyer, Olivier; Benoit, Jean Pierre.

In: Journal of Drug Targeting, 21.11.2018, p. 1-12.

Research output: Contribution to journalArticle

Lollo, G, Matha, K, Bocchiardo, M, Bejaud, J, Marigo, I, Virgone-Carlotta, A, Dehoux, T, Rivière, C, Rieu, JP, Briançon, S, Perrier, T, Meyer, O & Benoit, JP 2018, 'Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules', Journal of Drug Targeting, pp. 1-12. https://doi.org/10.1080/1061186X.2018.1547733
Lollo, Giovanna ; Matha, Kevin ; Bocchiardo, Martina ; Bejaud, Jérôme ; Marigo, Ilaria ; Virgone-Carlotta, Angelique ; Dehoux, Thomas ; Rivière, Charlotte ; Rieu, Jean Paul ; Briançon, Stephanie ; Perrier, Thomas ; Meyer, Olivier ; Benoit, Jean Pierre. / Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules. In: Journal of Drug Targeting. 2018 ; pp. 1-12.
@article{92bd54e58fac48469187ac428dfd3fd1,
title = "Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules",
abstract = "In this work, a novel lipophilic 5-fluorouracil (5-FU) derivative was synthesised and encapsulated into lipid nanocapsules (LNC). 5-FU was modified with lauric acid to give a lipophilic mono-lauroyl-derivative (5-FU-C12, MW of about 342 g/mol, yield of reaction 70{\%}). 5-FU-C12 obtained was efficiently encapsulated into LNC (encapsulation efficiency above 90{\%}) without altering the physico-chemical characteristics of LNC. The encapsulation of 5-FU-C12 led to an increased stability of the drug when in contact with plasma being the drug detectable until 3 h following incubation. Cytotoxicity assay carried out using MTS on 2D cell culture showed that 5-FU-C12-loaded LNC had an enhanced cytotoxic effect on glioma (9L) and human colorectal (HTC-116) cancer cell line in comparison with 5-FU or 5-FU-C12. Then, HCT-116 tumour spheroids were cultivated and the reduction of spheroid volume was measured following treatment with drug-loaded LNC and drugs alone. Similar reduction on spheroids volume was observed following the treatment with drug-loaded LNC, 5-FU-C12 and 5-FU alone, while blank LNC displayed a reduction in cell viability only at high concentration. Globally, our data suggest that the encapsulation increased the activity of the 5-FU-C12. However, in-depth evaluations of LNC permeability into spheroids are needed to disclose the potential of these nanosystems for cancer treatment.",
keywords = "5-Fluorouracil, cancer treatment, lipid nanoparticles, nanomedicine",
author = "Giovanna Lollo and Kevin Matha and Martina Bocchiardo and J{\'e}r{\^o}me Bejaud and Ilaria Marigo and Angelique Virgone-Carlotta and Thomas Dehoux and Charlotte Rivi{\`e}re and Rieu, {Jean Paul} and Stephanie Brian{\cc}on and Thomas Perrier and Olivier Meyer and Benoit, {Jean Pierre}",
year = "2018",
month = "11",
day = "21",
doi = "10.1080/1061186X.2018.1547733",
language = "English",
pages = "1--12",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules

AU - Lollo, Giovanna

AU - Matha, Kevin

AU - Bocchiardo, Martina

AU - Bejaud, Jérôme

AU - Marigo, Ilaria

AU - Virgone-Carlotta, Angelique

AU - Dehoux, Thomas

AU - Rivière, Charlotte

AU - Rieu, Jean Paul

AU - Briançon, Stephanie

AU - Perrier, Thomas

AU - Meyer, Olivier

AU - Benoit, Jean Pierre

PY - 2018/11/21

Y1 - 2018/11/21

N2 - In this work, a novel lipophilic 5-fluorouracil (5-FU) derivative was synthesised and encapsulated into lipid nanocapsules (LNC). 5-FU was modified with lauric acid to give a lipophilic mono-lauroyl-derivative (5-FU-C12, MW of about 342 g/mol, yield of reaction 70%). 5-FU-C12 obtained was efficiently encapsulated into LNC (encapsulation efficiency above 90%) without altering the physico-chemical characteristics of LNC. The encapsulation of 5-FU-C12 led to an increased stability of the drug when in contact with plasma being the drug detectable until 3 h following incubation. Cytotoxicity assay carried out using MTS on 2D cell culture showed that 5-FU-C12-loaded LNC had an enhanced cytotoxic effect on glioma (9L) and human colorectal (HTC-116) cancer cell line in comparison with 5-FU or 5-FU-C12. Then, HCT-116 tumour spheroids were cultivated and the reduction of spheroid volume was measured following treatment with drug-loaded LNC and drugs alone. Similar reduction on spheroids volume was observed following the treatment with drug-loaded LNC, 5-FU-C12 and 5-FU alone, while blank LNC displayed a reduction in cell viability only at high concentration. Globally, our data suggest that the encapsulation increased the activity of the 5-FU-C12. However, in-depth evaluations of LNC permeability into spheroids are needed to disclose the potential of these nanosystems for cancer treatment.

AB - In this work, a novel lipophilic 5-fluorouracil (5-FU) derivative was synthesised and encapsulated into lipid nanocapsules (LNC). 5-FU was modified with lauric acid to give a lipophilic mono-lauroyl-derivative (5-FU-C12, MW of about 342 g/mol, yield of reaction 70%). 5-FU-C12 obtained was efficiently encapsulated into LNC (encapsulation efficiency above 90%) without altering the physico-chemical characteristics of LNC. The encapsulation of 5-FU-C12 led to an increased stability of the drug when in contact with plasma being the drug detectable until 3 h following incubation. Cytotoxicity assay carried out using MTS on 2D cell culture showed that 5-FU-C12-loaded LNC had an enhanced cytotoxic effect on glioma (9L) and human colorectal (HTC-116) cancer cell line in comparison with 5-FU or 5-FU-C12. Then, HCT-116 tumour spheroids were cultivated and the reduction of spheroid volume was measured following treatment with drug-loaded LNC and drugs alone. Similar reduction on spheroids volume was observed following the treatment with drug-loaded LNC, 5-FU-C12 and 5-FU alone, while blank LNC displayed a reduction in cell viability only at high concentration. Globally, our data suggest that the encapsulation increased the activity of the 5-FU-C12. However, in-depth evaluations of LNC permeability into spheroids are needed to disclose the potential of these nanosystems for cancer treatment.

KW - 5-Fluorouracil

KW - cancer treatment

KW - lipid nanoparticles

KW - nanomedicine

UR - http://www.scopus.com/inward/record.url?scp=85057587371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057587371&partnerID=8YFLogxK

U2 - 10.1080/1061186X.2018.1547733

DO - 10.1080/1061186X.2018.1547733

M3 - Article

AN - SCOPUS:85057587371

SP - 1

EP - 12

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

ER -